The HealthTech Signal
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Chai Discovery triples its valuation as pharma buys into AI-designed molecules
Dr. Dereck Mush, MD, MBA
Profluent
Generates custom proteins and gene-editing systems using deep learning models.
What they do
Profluent applies generative AI, trained on massive protein sequence datasets, to design entirely new biomolecules. Biopharma companies and research laboratories use the platform to develop customized proteins and CRISPR-like gene editors optimized for specific therapeutic functions.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Protein design
- Product type
- Platform software
- Stage
- Series A
- Headquarters
- Berkeley, USA
- Region
- North America
- Founded
- 2022
- Total funding
- $44M raised
Notable investors: Spark Capital, Insight Partners, Air Street Capital, AIX Ventures.
Also in Pharma & Drug Discovery
Related on The Signal
Dr. Dereck Mush, MD, MBA
Bypassing Carrier Suppression: The 31-Valent Conjugate Architecture Reshaping Pneumococcal Vaccinology
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA
What Pharma Is Buying From AI Drug Discovery: Inside AstraZeneca’s insitro Deal
Dr. Dereck Mush, MD, MBA